The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, California, from August 25-27. This meeting brought together leading experts in the field of multiple myeloma to discuss and present preclinical and clinical data, as well as novel approaches in the treatment and diagnosis of myeloma.
View all videos

IMS 2022

The 19th International Myeloma Society Annual Meeting
25–27 August 2022 | Los Angeles, California
VJHemOncVJHemOnc@VJHemOnc·
4h

🎥 @BrunoPaiva_UNAV discusses the results of a pooled analysis of the TOURMALINE-MM3 and MM4 trials at #IMS2022:

👉http://ow.ly/iHYt50KVQEy👈

@Myeloma_Society #MMsm #HemOnc #mmMRD #BloodCancerAwarenessMonth

Reply on Twitter 1575380146521083906Retweet on Twitter 15753801465210839062Like on Twitter 15753801465210839063View Tweet 1575380146521083906
Retweet on TwitterVJHemOnc Retweeted
MDmasarovaLucia Masarova, MD@MDmasarova·
8h

@VJHemOnc @SocietyofHemOnc Thank you @VJHemOnc for the connection, opportunity and chat. So much to talk about #MPN but more to do! Great job presenting the hot topics in #leusm #SOHO2022👍

Reply on Twitter 1575320546358824966Retweet on Twitter 15753205463588249661Like on Twitter 15753205463588249661View Tweet 1575320546358824966
Retweet on TwitterVJHemOnc Retweeted
Radhika_BanslRadhika Bansal-Rakshit (She/Her)@Radhika_Bansl·
13h

📍#CART in #AML

🔭 A look into the future 🌎 with @kenderian_ss @SocietyofHemOnc #SOHO2022 @MayoCancerCare #hematology #cancerResearch #Research #MedTwitter

4
Reply on Twitter 1575244201926791183Retweet on Twitter 15752442019267911832Like on Twitter 15752442019267911837View Tweet 1575244201926791183
Load More...

IMS 2022

The 19th International Myeloma Society Annual Meeting
25–27 August 2022 | Los Angeles, California
The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, California, from August 25-27. This meeting brought together leading experts in the field of multiple myeloma to discuss and present preclinical and clinical data, as well as novel approaches in the treatment and diagnosis of myeloma.
View all videos
VJHemOncVJHemOnc@VJHemOnc·
4h

🎥 @BrunoPaiva_UNAV discusses the results of a pooled analysis of the TOURMALINE-MM3 and MM4 trials at #IMS2022:

👉http://ow.ly/iHYt50KVQEy👈

@Myeloma_Society #MMsm #HemOnc #mmMRD #BloodCancerAwarenessMonth

Reply on Twitter 1575380146521083906Retweet on Twitter 15753801465210839062Like on Twitter 15753801465210839063View Tweet 1575380146521083906
Retweet on TwitterVJHemOnc Retweeted
MDmasarovaLucia Masarova, MD@MDmasarova·
8h

@VJHemOnc @SocietyofHemOnc Thank you @VJHemOnc for the connection, opportunity and chat. So much to talk about #MPN but more to do! Great job presenting the hot topics in #leusm #SOHO2022👍

Reply on Twitter 1575320546358824966Retweet on Twitter 15753205463588249661Like on Twitter 15753205463588249661View Tweet 1575320546358824966
Retweet on TwitterVJHemOnc Retweeted
Radhika_BanslRadhika Bansal-Rakshit (She/Her)@Radhika_Bansl·
13h

📍#CART in #AML

🔭 A look into the future 🌎 with @kenderian_ss @SocietyofHemOnc #SOHO2022 @MayoCancerCare #hematology #cancerResearch #Research #MedTwitter

4
Reply on Twitter 1575244201926791183Retweet on Twitter 15752442019267911832Like on Twitter 15752442019267911837View Tweet 1575244201926791183
Load More...

Latest videos

View all
2:28
Clonal hematopoiesis and implications in multiple myeloma
Adam Sperling • 26 Aug 2022
1:57
Key genetic changes that elicit the transformation of plasma cells in myeloma
Adam Sperling • 26 Aug 2022
2:21
The role of daratumumab in the treatment of myeloma and insights into the MAIA trial
Saad Usmani • 25 Aug 2022
1:13
The importance of bone disease control in multiple myeloma
Artur Jurczyszyn • 26 Aug 2022

CAR-T Therapy

View all
3:15
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier • 27 Aug 2022
1:35
Patient responses to CAR-T therapy and factors that may influence these responses
Yi Lin • 25 Aug 2022

Antibody-based therapy

View all
2:30
Daratumumab and isatuximab in the treatment of multiple myeloma
Mohamad Mohty • 25 Aug 2022
2:04
Approval of teclistamab in triple-class refractory multiple myeloma
Maria-Victoria Mateos • 26 Aug 2022

MRD

View all
2:21
The role of daratumumab in the treatment of myeloma and insights into the MAIA trial
Saad Usmani • 25 Aug 2022
2:07
Key findings of the pooled analysis of the TOURMALINE-MM3 and MM4 trials
Bruno Paiva • 25 Aug 2022

Trial Updates

View all
2:21
The role of daratumumab in the treatment of myeloma and insights into the MAIA trial
Saad Usmani • 25 Aug 2022
1:34
Treatment strategies for frail and elderly myeloma patients
Salomon Manier • 27 Aug 2022

Amyloidosis

View all
1:20
Outcomes of renal transplantation in patients with AL amyloidosis
Nelson Leung • 25 Aug 2022
3:21
Insights into the management of systemic AL amyloidosis
Sandy Wong • 26 Aug 2022

Waldenström’s Macroglobulinemia

View all
1:24
The long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated WM
Steven Treon • 25 Aug 2022
1:30
Bendamustine-rituximab vs ibrutinib as frontline therapy in Waldenström’s macroglobulinemia
Steven Treon • 25 Aug 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals